The current way to make a highly targeted type of drug called “antibody-drug conjugates” is lengthy and inefficient. Scientists at the USC School of Pharmacy have engineered something better.
A USC School of Pharmacy-led team has engineered a new, faster way to make drugs that precisely target malignant cells — while leaving healthy tissue undamaged — that could lead the way to better treatments for numerous types of cancer.
The drugs, called antibody-drug conjugates (ADCs), belong to a relatively new class in which drug molecules are attached to antibodies that focus on and attach to the surface of cancer cells. As of May 2020, eight ADCs have been approved by the Food and Drug Administration and more than 100 clinical trials are underway studying their effectiveness in treating blood, lung, breast, brain and other cancers.
In a study published today in Science Advances, USC scientists describe a new technology to rapidly create a homogeneous type of ADC in high efficiency, which features drugs attached at a specific site on the antibodies and potentially enhanced stability, effectiveness and safety.
Antibody-drug conjugates present a path to improved precision cancer treatment
ADCs consist of an antibody for seeking out a cancer cell, a drug for killing it and a chemical “linker” uniting them. However, currently used ADCs are manufactured through a process that yields varied products of limited stability and efficacy.
Homogenous ADCs therefore carry more potential for clinical effectiveness. But current technologies for making this type of ADC require multiple steps or long reaction times due to inefficient chemistries. Many homogenous ADCs can also trigger immune responses that hamper their use.
The USC team may have solved these issues.
“Using our approach, homogenous ADCs could be made through a single-step reaction in less than two hours, much faster and more efficiently than conventional approaches,” said principal investigator Yong (Tiger) Zhang, assistant professor of pharmacology and pharmaceutical sciences at the USC School of Pharmacy.
“Our technology features a designer ‘linker’ component exclusively recognized by a human enzyme that can rapidly catalyze the conjugation of drug molecules to the antibodies at a defined position,” he said. “In addition to its fast rate and high efficiency, our ADC technology offers a new type of linker for connecting the drugs to antibodies. This designer linker ensures stable attachment of the drug and rapid release of the drugs into target cells, making the generated ADCs safer and more efficacious.”
Using this technology, the USC team generated an ADC that can effectively block the growth of breast cancer tumors in animals. The investigators say these promising results provide a strong basis for translation of this ADC into clinical studies.
The research was supported by the USC School of Pharmacy Start-Up Fund for New Faculty, Sharon L. Cockrell Cancer Research Fund, The V Foundation for Cancer Research V Scholar Grant (V2016-021), STOP CANCER Research Career Development Award, and PhRMA Foundation Research Starter Grant in Translational Medicine and Therapeutics.
Additional USC authors were Zhefu Dai, Xiao-Nan Zhang, Qinqin Cheng, Jiawei Lei, Hua Pei and Stan G. Louie of the USC School of Pharmacy; Fariborz Nasertorabi and Raymond C. Stevens of the USC Bridge Institute at the USC Michelson Center for Convergent Bioscience; and Goar Smbatyan and Heinz-Josef Lenz of the Keck School of Medicine of USC.